PT2474521T - 2-[4-(3- e 2-fluorobenziloxi)benzilamino]propanamidas de grau de pureza elevado para utilização como medicamentos e formulações farmacêuticas que as contêm - Google Patents

2-[4-(3- e 2-fluorobenziloxi)benzilamino]propanamidas de grau de pureza elevado para utilização como medicamentos e formulações farmacêuticas que as contêm

Info

Publication number: PT2474521T
Authority: PT; Portugal
Prior art keywords: propanamides; fluorobenzyloxy; benzylamino; medicaments; high purity
Prior art date: 2006-06-19

Application number

PT121630859T

Other languages

English (en)

Inventor

Caccia Carla

Salvati Patrícia

Velardi Francesco

Ruffilli Tiziano

Bogogna Luigi

Barbanti Elena

Original Assignee

Newron Pharm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-19

Filing date

2007-06-08

Publication date

2016-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2474521(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-08 Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa

2016-11-10 Publication of PT2474521T publication Critical patent/PT2474521T/pt

Links

-1 2-fluorobenzyloxy Chemical group 0.000 title 1
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title 1
239000003814 drug Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT121630859T 2006-06-19 2007-06-08 2-[4-(3- e 2-fluorobenziloxi)benzilamino]propanamidas de grau de pureza elevado para utilização como medicamentos e formulações farmacêuticas que as contêm PT2474521T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06012565		2006-06-19

Publications (1)

Publication Number	Publication Date
PT2474521T true PT2474521T (pt)	2016-11-10

Family

ID=37101658

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT121630859T PT2474521T (pt)	2006-06-19	2007-06-08	2-[4-(3- e 2-fluorobenziloxi)benzilamino]propanamidas de grau de pureza elevado para utilização como medicamentos e formulações farmacêuticas que as contêm
PT07764601T PT2029524E (pt)	2006-06-19	2007-06-08	Processo para a produção de 2-[4-(3- e 2-fluorobenziloxi benzilamino]propanamidas

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT07764601T PT2029524E (pt)	2006-06-19	2007-06-08	Processo para a produção de 2-[4-(3- e 2-fluorobenziloxi benzilamino]propanamidas

Country Status (26)

Country	Link
US (2)	US8076515B2 (pt)
EP (2)	EP2474521B1 (pt)
JP (2)	JP5240476B2 (pt)
KR (2)	KR101410291B1 (pt)
CN (2)	CN103284984B (pt)
AR (1)	AR061510A1 (pt)
AU (1)	AU2007263328C1 (pt)
BR (1)	BRPI0712936B8 (pt)
CA (1)	CA2653012C (pt)
CY (2)	CY1115951T1 (pt)
DK (2)	DK2474521T3 (pt)
EA (2)	EA017123B1 (pt)
ES (2)	ES2527437T3 (pt)
HR (2)	HRP20150136T1 (pt)
HU (1)	HUE030233T2 (pt)
IL (1)	IL195294A (pt)
LT (1)	LT2474521T (pt)
MX (2)	MX342698B (pt)
NO (2)	NO342018B1 (pt)
NZ (2)	NZ572798A (pt)
PL (2)	PL2029524T3 (pt)
PT (2)	PT2474521T (pt)
RS (2)	RS53824B1 (pt)
SI (2)	SI2474521T1 (pt)
TW (2)	TWI393700B (pt)
WO (1)	WO2007147491A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2339021T3 (es) *	2003-08-25	2010-05-14	Newron Pharmaceuticals S.P.A.	Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
DK2474521T3 (en) *	2006-06-19	2016-10-31	Newron Pharm Spa	High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus
KR101593627B1 (ko)	2007-12-11	2016-02-11	뉴론 파마슈티칼즈 에스. 피. 에이.	고순도의 ２［４（３ 또는 ２플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법
EP2314569A1 (en)	2009-10-22	2011-04-27	Merck Patent GmbH	Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
NZ602648A (en) *	2010-04-27	2014-10-31	Newron Pharm Spa	Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
WO2014086704A1 (en)	2012-12-03	2014-06-12	F. Hoffmann-La Roche Ag	Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1)
US9475757B2 (en)	2013-05-03	2016-10-25	Council Of Scientific & Industrial Research	Synthesis of anti-Parkinson agent
CN104292128A (zh) *	2014-07-01	2015-01-21	南京正科制药有限公司	一种沙芬酰胺晶型a
JP6466109B2 (ja) *	2014-09-09	2019-02-06	東ソー・ファインケム株式会社	２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105017060B (zh) *	2015-07-03	2017-06-16	南京正大天晴制药有限公司	一种沙芬酰胺新晶型及其制备方法
CN106365966A (zh) *	2015-07-24	2017-02-01	上海医药集团股份有限公司	一种苄基芳基醚的制备方法
CN105061245A (zh) *	2015-08-25	2015-11-18	成都维恒医药科技有限公司	一种高纯度沙芬酰胺的制备方法
CN106220525A (zh) *	2016-07-31	2016-12-14	合肥远志医药科技开发有限公司	一种工业化沙芬酰胺甲磺酸盐的制备方法
CN106336363B (zh) *	2016-08-22	2018-10-30	上海医药集团股份有限公司	一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN106565521B (zh) *	2016-08-24	2019-03-08	浙江美诺华药物化学有限公司	(s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106596828B (zh) *	2016-12-15	2018-09-25	扬子江药业集团有限公司	一种甲磺酸沙芬酰胺有关物质的检测方法
CN107271600B (zh) *	2017-07-28	2019-01-25	成都百裕制药股份有限公司	一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法
CN107759487A (zh) *	2017-11-23	2018-03-06	江苏恒盛药业有限公司	一种沙芬酰胺盐酸盐及其一种晶型以及制备方法
CN107857713A (zh) *	2017-11-23	2018-03-30	江苏恒盛药业有限公司	一种沙芬酰胺氢溴酸盐及其一种晶型
WO2019167085A1 (en) *	2018-03-01	2019-09-06	Msn Laboratories Private Limited, R&D Center	Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
US11111208B2 (en)	2019-06-17	2021-09-07	RK Pharma Solutions LLC	Process for the preparation of safinamide mesylate intermediate
ES2977486T3 (es)	2019-08-06	2024-08-26	Medichem Sa	Proceso para preparar safinamida
CN111122736B (zh) *	2019-12-30	2021-03-12	北京鑫开元医药科技有限公司海南分公司	一种用于检测布瓦西坦中间体中对映异构体的方法
CN113214097B (zh) *	2020-01-21	2022-08-30	厦门大学	治疗阿尔茨海默病的化合物
CN112028754A (zh) *	2020-06-17	2020-12-04	浙江美诺华药物化学有限公司	一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) *	2021-11-10	2022-09-23	石家庄四药有限公司	一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法
CN117923998A (zh) *	2022-10-24	2024-04-26	中国石油化工股份有限公司	苯甲醛及其衍生物的制备方法
CN116008439B (zh) *	2023-02-20	2023-10-27	山东绿叶制药有限公司	一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法
AU2024298771A1 (en)	2023-07-25	2026-01-22	Intas Pharmaceuticals Ltd.	An orodispersible pharmaceutical solid dosage form of safinamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL94466A (en) *	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) *	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
EP0974351A3 (en) *	1998-04-24	2000-12-13	Jouveinal	Medicament for preventing and treating gastrointestinal damage
NZ521870A (en)	2000-03-31	2004-08-27	Euro Celtique S	Aminopyridines and their use as anticonvulsants and sodium channel blockers
SI1423168T1 (sl)	2001-09-03	2006-06-30	Newron Pharm Spa	Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
EP1438956A1 (en)	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful as antimigraine agents
US20040209960A1 (en) *	2003-01-30	2004-10-21	Dynogen Pharmaceuticals, Inc.	Methods of treating lower urinary tract disorders using sodium channell modulators
JP2006515326A (ja) *	2003-01-30	2006-05-25	ダイノジェンファーマシューティカルズ，インコーポレイテッド	胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
AR044007A1 (es) *	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) *	2003-07-25	2005-03-01	Kyowa Hakko Kogyo Kk	Pharmaceutical composition
ES2339021T3 (es)	2003-08-25	2010-05-14	Newron Pharmaceuticals S.P.A.	Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1524267A1 (en)	2003-10-15	2005-04-20	Newron Pharmaceuticals S.p.A.	Substituted benzylaminoalkylene heterocycles
EP1557166A1 (en) *	2004-01-21	2005-07-27	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) *	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US20080096965A1 (en)	2004-09-10	2008-04-24	Newron Pharmaceuticals S.P.A.	(Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
EP1870097A1 (en) *	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
DK2474521T3 (en) *	2006-06-19	2016-10-31	Newron Pharm Spa	High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus
KR101593627B1 (ko) *	2007-12-11	2016-02-11	뉴론 파마슈티칼즈 에스. 피. 에이.	고순도의 ２［４（３ 또는 ２플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법
CA2707646C (en) *	2007-12-19	2016-09-13	Newron Pharmaceuticals S.P.A.	Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders

2007
- 2007-06-08 DK DK12163085.9T patent/DK2474521T3/en active
- 2007-06-08 RS RS20150114A patent/RS53824B1/sr unknown
- 2007-06-08 EA EA200970028A patent/EA017123B1/ru unknown
- 2007-06-08 DK DK07764601.6T patent/DK2029524T3/da active
- 2007-06-08 BR BRPI0712936A patent/BRPI0712936B8/pt active IP Right Grant
- 2007-06-08 CA CA2653012A patent/CA2653012C/en active Active
- 2007-06-08 RS RS20160965A patent/RS55464B1/sr unknown
- 2007-06-08 EP EP12163085.9A patent/EP2474521B1/en active Active
- 2007-06-08 NZ NZ572798A patent/NZ572798A/en unknown
- 2007-06-08 PT PT121630859T patent/PT2474521T/pt unknown
- 2007-06-08 CN CN201310142245.3A patent/CN103284984B/zh active Active
- 2007-06-08 HR HRP20150136TT patent/HRP20150136T1/hr unknown
- 2007-06-08 ES ES07764601.6T patent/ES2527437T3/es active Active
- 2007-06-08 EA EA201101308A patent/EA025326B1/ru unknown
- 2007-06-08 WO PCT/EP2007/005105 patent/WO2007147491A1/en not_active Ceased
- 2007-06-08 JP JP2009515731A patent/JP5240476B2/ja active Active
- 2007-06-08 HU HUE12163085A patent/HUE030233T2/en unknown
- 2007-06-08 MX MX2012005094A patent/MX342698B/es unknown
- 2007-06-08 SI SI200731854A patent/SI2474521T1/sl unknown
- 2007-06-08 LT LTEP12163085.9T patent/LT2474521T/lt unknown
- 2007-06-08 PL PL07764601T patent/PL2029524T3/pl unknown
- 2007-06-08 CN CN2007800228798A patent/CN101472880B/zh not_active Ceased
- 2007-06-08 ES ES12163085.9T patent/ES2602069T3/es active Active
- 2007-06-08 SI SI200731603T patent/SI2029524T1/sl unknown
- 2007-06-08 KR KR1020097001124A patent/KR101410291B1/ko active Active
- 2007-06-08 EP EP07764601.6A patent/EP2029524B1/en active Active
- 2007-06-08 KR KR20147003965A patent/KR101491541B1/ko active Active
- 2007-06-08 MX MX2008015704A patent/MX2008015704A/es active IP Right Grant
- 2007-06-08 PL PL12163085T patent/PL2474521T3/pl unknown
- 2007-06-08 AU AU2007263328A patent/AU2007263328C1/en active Active
- 2007-06-08 NZ NZ595737A patent/NZ595737A/xx unknown
- 2007-06-08 PT PT07764601T patent/PT2029524E/pt unknown
- 2007-06-15 TW TW096121879A patent/TWI393700B/zh active
- 2007-06-15 TW TW101148004A patent/TWI412512B/zh active
- 2007-06-19 AR ARP070102674A patent/AR061510A1/es active IP Right Grant
2008
- 2008-11-13 IL IL195294A patent/IL195294A/en active Protection Beyond IP Right Term
- 2008-12-18 US US12/338,825 patent/US8076515B2/en active Active
2009
- 2009-01-14 NO NO20090231A patent/NO342018B1/no unknown
2011
- 2011-11-03 US US13/288,891 patent/US8278485B2/en active Active
2013
- 2013-01-10 JP JP2013002429A patent/JP5795342B2/ja active Active
2015
- 2015-01-23 CY CY20151100072T patent/CY1115951T1/el unknown
2016
- 2016-10-18 CY CY20161101038T patent/CY1118113T1/el unknown
- 2016-11-03 HR HRP20161456TT patent/HRP20161456T1/hr unknown
2017
- 2017-11-30 NO NO20171916A patent/NO342644B1/no unknown

Also Published As

Publication number	Publication date
CY1115951T1 (el)	2017-01-25
PL2474521T3 (pl)	2017-01-31
JP5795342B2 (ja)	2015-10-14
HRP20161456T1 (hr)	2016-12-16
PL2029524T3 (pl)	2015-04-30
CY1118113T1 (el)	2017-06-28
NO20171916A1 (no)	2009-01-16
LT2474521T (lt)	2016-11-25
US8278485B2 (en)	2012-10-02
EA025326B1 (ru)	2016-12-30
DK2029524T3 (da)	2015-02-23
AU2007263328A1 (en)	2007-12-27
ES2527437T3 (es)	2015-01-26
JP2013139446A (ja)	2013-07-18
US20120157712A1 (en)	2012-06-21
CA2653012A1 (en)	2007-12-27
PT2029524E (pt)	2015-03-09
AU2007263328A2 (en)	2009-02-19
NZ595737A (en)	2013-04-26
HK1130245A1 (en)	2009-12-24
AU2007263328C1 (en)	2012-09-06
NO342644B1 (no)	2018-06-25
EP2474521A1 (en)	2012-07-11
BRPI0712936B1 (pt)	2021-02-23
CA2653012C (en)	2014-08-05
NZ572798A (en)	2011-11-25
JP2009541232A (ja)	2009-11-26
HUE030233T2 (en)	2017-04-28
CN101472880B (zh)	2013-04-24
US20090156678A1 (en)	2009-06-18
TWI393700B (zh)	2013-04-21
SI2029524T1 (sl)	2015-03-31
KR101410291B1 (ko)	2014-06-20
AR061510A1 (es)	2008-09-03
EP2474521B1 (en)	2016-08-10
NO342018B1 (no)	2018-03-12
ES2602069T3 (es)	2017-02-17
EA017123B1 (ru)	2012-10-30
KR20140027563A (ko)	2014-03-06
EP2029524B1 (en)	2014-11-26
EA201101308A1 (ru)	2012-02-28
BRPI0712936B8 (pt)	2021-05-25
CN101472880A (zh)	2009-07-01
CN103284984B (zh)	2016-08-03
NO20090231L (no)	2009-01-16
KR20090021392A (ko)	2009-03-03
MX2008015704A (es)	2009-01-09
BRPI0712936A2 (pt)	2012-12-18
TW200815322A (en)	2008-04-01
TWI412512B (zh)	2013-10-21
RS55464B1 (sr)	2017-04-28
DK2474521T3 (en)	2016-10-31
IL195294A (en)	2015-03-31
KR101491541B1 (ko)	2015-02-09
EP2029524A1 (en)	2009-03-04
JP5240476B2 (ja)	2013-07-17
CN103284984A (zh)	2013-09-11
US8076515B2 (en)	2011-12-13
MX342698B (es)	2016-10-10
WO2007147491A1 (en)	2007-12-27
AU2007263328B2 (en)	2012-03-22
RS53824B1 (sr)	2015-06-30
TW201313662A (zh)	2013-04-01
EA200970028A1 (ru)	2009-06-30
SI2474521T1 (sl)	2016-12-30
IL195294A0 (en)	2009-08-03
HRP20150136T1 (xx)	2015-03-13

Publication	Publication Date	Title
PL2474521T3 (pl)	2017-01-31	2-[4-(3- i 2-fluorobenzyloksy)benzyIoamino]propanoamidy o wysokim stopniu czystości do zastosowania jako leki i preparaty farmaceutyczne je zawierające
IL205872A (en)	2015-06-30	Process for the preparation of compounds 2- [4- (3- or 2-fluorobenzyloxy) benzylamino] high-purity propanamide, medicinal preparations containing them, and their use in the preparation of drugs
IL185277A0 (en)	2008-02-09	Pharmaceutical compositions containing roflumilast for the treatment of diabetes
IL193894A0 (en)	2009-09-22	Pharmaceutical compositions containing luliconazole for external use
IL212435A (en)	2015-06-30	Isoindulin compounds, their pharmaceutical compositions and their use in the preparation of drugs
IL193762A (en)	2013-05-30	The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
IL199397A (en)	2014-07-31	Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products
IL233677A (en)	2016-11-30	Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
ZA200900345B (en)	2010-05-26	Preparation of pharmaceutical formulations
IL201581A0 (en)	2010-05-31	Pharmaceutical formulations containing lipoic acid derivatives
ZA200808530B (en)	2009-12-30	Pharmaceutical composition for external use
IL209054A0 (en)	2011-01-31	Solid pharmaceutical formulations comprising bibw 2992
IL194546A0 (en)	2009-08-03	Arylaminopyridine derivatives and pharmaceutical compositions containing them
IL225198A (en)	2016-02-29	Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
IL205742A (en)	2014-12-31	4 - (4-Cyano-2-Theoaryl) dihydropyrimidinones, their preparation processes, medications containing them and their use
IL212573A (en)	2015-01-29	Aryl Methyl Benzokinazulinone Compounds
IL195947A (en)	2013-07-31	Manicured cyclic compounds and pharmaceutical preparations containing them for use @ for prevention @ and treatment @ for diabetes
IL199362A (en)	2013-07-31	Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
ZA200810166B (en)	2009-08-26	Phenylephrine pharmaceutical formulations and compositions for colonic absorption
IL188980A0 (en)	2008-08-07	Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
PL1874746T3 (pl)	2016-06-30	Pochodne 1-N-azacykloalkilo-3-fenoksypropanu użyteczne do wytwarzania leków psychotropowych
IL206562A0 (en)	2010-12-30	Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
IL187534A0 (en)	2008-03-20	Thiazole derivatives, use thereof and pharmaceutical compositions containing them
IL218745A0 (en)	2012-05-31	Pharmaceutical compositions containing roflumilast
ZA200807486B (en)	2009-11-25	Medicament formulations comprising fluoroquinolones